Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study

Trial Profile

Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Afatinib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2016 This trial is completed in Italy ( end date: 28 Apr 2016).
    • 07 Jun 2016 Results of preliminary analysis in patients with newly diagnosed squamous cell carcinoma of the head and neck presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top